Imatinib is the standard first-line systemic treatment for chronic myeloid leukemia and Gastrointestinal Stromal Tumor (GIST), targeting BCR-ABL and c-KIT tyrosine kinases, respectively. Here, KIT is linked to gastrointestinal stromal tumor.